Leqembi’s FDA Approval Opens The Door To Expanded Medicare Coverage For Alzheimer’s Patients
Leqembi, a pricey medication used to treat Alzheimer’s, has been completely approved by the Food and Drug Administration, a significant move that will increase elderly Americans’ access to it. The antibody treatment is currently being covered by Medicare for individuals registered in the insurance programme for seniors, albeit there are a few restrictions, it was disclosed immediately after the FDA clearance. The first Alzheimer’s antibody therapy to get complete FDA clearance is Leqembi. It is also the first such medication to be given extensive reimbursement by Medicare. There is no cure for leqembi. In the course of Eisai’s clinical trial, the medication reduced the rate of cognitive deterioration brought on by early-stage Alzheimer’s disease by 27%. The antibody, which is given intravenously every two months, targets a molecule called amyloid that is linked to Alzheimer’s disease. In order to assist older Americans with early-stage Alzheimer’s disease with treatment costs, M...